Ivermectin and Pharmacological Ascorbate in Cancer: Mechanistic Insights, Translational Challenges, and the Rationale for Future Combination Studies

The need for more effective cancer treatments has led to growing interest in drug repurposing and therapeutic approaches targeting cancer metabolism. Ivermectin and high-dose vitamin C have both been investigated for their possible anticancer effects. Ivermectin is an established antiparasitic drug, while vitamin C is an essential nutrient. Studies in experimental cancer models suggest that these compounds can affect cell survival through changes in oxidative stress, mitochondrial activity, metabolism and cell-death pathways. High-dose intravenous vitamin C differs from ordinary supplementation because it can reach millimolar concentrations in the blood. At these levels, ascorbate can promote hydrogen peroxide formation outside cells, increasing oxidative stress in susceptible cancer cells. Vitamin C also supports the activity of certain enzymes that depend on iron and 2-oxoglutarate. These enzymes are involved in the control of gene activity, cell development, and the way cells respond to oxygen levels. Although ivermectin and pharmacological ascorbate act through different mechanisms, some of their effects involve similar biological processes. Both have been associated with increased reactive oxygen species (ROS) production, mitochondrial dysfunction, activation of programmed cell death and changes in signalling pathways involved in cancer progression. This narrative review examines the molecular mechanisms, preclinical evidence, pharmacological limitations, and clinical experience associated with each compound. No direct preclinical or clinical cancer studies evaluating ivermectin and pharmacological ascorbate together were identified in the literature reviewed.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210298
Primary Topic
Vitamin C and Antioxidants Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ivermectin and Pharmacological Ascorbate in Cancer: Mechanistic Insights, Translational Challenges, and the Rationale for Future Combination Studies

Maria Rachele Ceccarini, Michela Codini, Tommaso Beccari, Eleonora Manuali
International Journal of Molecular Sciences
Vitamin C and Antioxidants Research
article

Ivermectin and Pharmacological Ascorbate in Cancer: Mechanistic Insights, Translational Challenges, and the Rationale for Future Combination Studies

Maria Rachele Ceccarini, Michela Codini, Tommaso Beccari, Eleonora Manuali
article en

Abstract

The need for more effective cancer treatments has led to growing interest in drug repurposing and therapeutic approaches targeting cancer metabolism. Ivermectin and high-dose vitamin C have both been investigated for their possible anticancer effects. Ivermectin is an established antiparasitic drug, while vitamin C is an essential nutrient. Studies in experimental cancer models suggest that these compounds can affect cell survival through changes in oxidative stress, mitochondrial activity, metabolism and cell-death pathways. High-dose intravenous vitamin C differs from ordinary supplementation because it can reach millimolar concentrations in the blood. At these levels, ascorbate can promote hydrogen peroxide formation outside cells, increasing oxidative stress in susceptible cancer cells. Vitamin C also supports the activity of certain enzymes that depend on iron and 2-oxoglutarate. These enzymes are involved in the control of gene activity, cell development, and the way cells respond to oxygen levels. Although ivermectin and pharmacological ascorbate act through different mechanisms, some of their effects involve similar biological processes. Both have been associated with increased reactive oxygen species (ROS) production, mitochondrial dysfunction, activation of programmed cell death and changes in signalling pathways involved in cancer progression. This narrative review examines the molecular mechanisms, preclinical evidence, pharmacological limitations, and clinical experience associated with each compound. No direct preclinical or clinical cancer studies evaluating ivermectin and pharmacological ascorbate together were identified in the literature reviewed.

International Journal of Molecular SciencesVol. 27(22)
University of Perugia (IT), Saint Camillus International University of Health and Medical Sciences (IT)
Good health and well-being
Vitamin C and Antioxidants Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon